Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00727948 · ClinicalTrials.gov registry record · Early Phase 1
The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy
A Early Phase 1 study, sponsored by University of Vermont.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT00727948 is a Early Phase 1 study that has completed, run by University of Vermont. The registered enrollment target is 11 participants.
The verdict
NCT00727948, a Early Phase 1 study, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Changes in major angiogenic proteins have been seen following initiation of tamoxifen and aromatase inhibitor therapy in women with breast cancer. One source of these proteins is the circulating platelet pool. The investigators hypothesize that in addition to their anti-platelet properties, agents such as aspirin can be used as targeted anti-angiogenesis therapy. The investigators will determine the influence of aspirin on the release of angiogenic proteins from platelets in 35 patients with breast cancer.
Interventions
- DRUG Aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00727948
The ClinicalTrials.gov registry entry for NCT00727948 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aspirin is the first listed.
NCT00727948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00727948 about?
NCT00727948 is a clinical study titled "The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy". Changes in major angiogenic proteins have been seen following initiation of tamoxifen and aromatase inhibitor therapy in women with breast cancer. One source of these proteins is the circulating platelet pool. The investigators hypothesize that in addition to their anti-platelet properties, agents s...
What is the current status of trial NCT00727948?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2008-07. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00727948?
The interventions under investigation include: Aspirin (DRUG).
Who is sponsoring clinical trial NCT00727948?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.